share_log
Moomoo 24/7 ·  Apr 16 07:02
IGC Pharma Announces Interim Phase 2 Data Showing IGC-AD1 Achieved Secondary Endpoint And Demonstrated A Clinical Reduction In Alzheimer's Agitation At Week Two
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment